{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-000192","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2024-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.946924+00:00","generated_at":"2026-06-07T04:34:04.674021+00:00","sec_items":["1.02","8.01","5.02","5.05","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Harrow terminates $18.4M Melt loan, takes ~47% equity stake; appoints Saharek division president","bullets":["Terminated Loan Agreement with Melt; received 2.26M Series B-1 and 74k Series B preferred shares in full settlement of ~$18.4M outstanding.","After settlement, Harrow holds ~47% of Melt's equity (including 3.5M common shares) plus royalty rights on Melt drug candidates.","John P. Saharek appointed President/CEO of ImprimisRx division effective Jan 2, 2024; base salary $450K, target bonus 50%.","Melt received FDA support for MELT-300 Phase 3 program; expects to begin Phase 3 in Q1 2024, potentially benefiting Harrow's stake.","Code of Business Conduct and Ethics amended to update corporate name and clarify political activities; no waivers granted."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-000192","json":"https://secwatch.observer/filing/0001493152-24-000192.json","markdown":"https://secwatch.observer/filing/0001493152-24-000192.md","text":"https://secwatch.observer/filing/0001493152-24-000192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000149315224000192/0001493152-24-000192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000149315224000192/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:34:04.674021+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10e05e25a2","claim":"John P. Saharek was appointed as President and Chief Executive Officer of the Company's ImprimisRx division at HARROW, INC..","evidence_excerpt":"Effective January 2, 2024, Harrow, Inc. (the “Company”) appointed John P. Saharek as the President and Chief Executive Officer of the Company’s ImprimisRx division, in addition to his current role as Chief Commercial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1360214/000149315224000192/0001493152-24-000192-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer of the Company's ImprimisRx division"}],"fact_type":"executive_change"},{"claim_id":"2361c1703a7202a4d172fe7b34bca6cd520a640c","claim":"HARROW, INC.: Amendments to the Code of Business Conduct and Ethics to update corporate name and clarify obligations regarding political activities (effective 2023-12-28).","evidence_excerpt":"Effective December 28, 2023, the Board of Directors of the Company approved certain amendments to the Company’s Code of Business Conduct and Ethics (the “Code”) upon the recommendation of the Nomination and Corporate Governance Committee of the Board.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1360214/000149315224000192/0001493152-24-000192-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"},{"label":"Effective","value":"2023-12-28"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}